Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Preferred Stock Liabilities: 2019

Historic Preferred Stock Liabilities for Keros Therapeutics (KROS) over the last 1 years, with Dec 2019 value amounting to $19.9 million.

  • Keros Therapeutics' Preferred Stock Liabilities rose 665.56% to $75.7 million in Q1 2020 from the same period last year, while for Mar 2020 it was $75.7 million, marking a year-over-year increase of 665.56%. This contributed to the annual value of $19.9 million for FY2019, which is N/A change from last year.
  • Per Keros Therapeutics' latest filing, its Preferred Stock Liabilities stood at $19.9 million for FY2019.
  • Keros Therapeutics' 5-year Preferred Stock Liabilities high stood at $19.9 million for FY2019, and its period low was $19.9 million during FY2019.
  • Its 1-year average for Preferred Stock Liabilities is $19.9 million, with a median of $19.9 million in 2019.